# Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

Study · id `cardio:ct-nct06676696` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06676696](<https://clinicaltrials.gov/study/NCT06676696>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06676696

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 202 participants.

## Technical summary

Registry record NCT06676696. Randomized; no masking; primary purpose treatment. Start 2024-01-22 (actual); primary completion 2028-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 202 participants (planned count; ClinicalTrials.gov record NCT06676696, source copy `cardio:ctgov-nct06676696-2024-11-06`, retrieved 2026-10-26)
- Started: 2024-01-22 (actual) (ClinicalTrials.gov record NCT06676696, source copy `cardio:ctgov-nct06676696-2024-11-06`, retrieved 2026-10-26)
- Primary completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT06676696, source copy `cardio:ctgov-nct06676696-2024-11-06`, retrieved 2026-10-26)
- Completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT06676696, source copy `cardio:ctgov-nct06676696-2024-11-06`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT06676696, source copy `cardio:ctgov-nct06676696-2024-11-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06676696-2024-11-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure
- Condition: Renal Failure , Chronic
- Condition: Graft Failure
- Condition: Graft Rejection
- Condition: Allograft
- Condition: Renal Failure Chronic Requiring Dialysis
- Intervention (Drug): Continue low dose calcineurin inhibitor (CNI)
- Intervention (Drug): Calcineurin inhibitor withdrawal at 6 months
- Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Hospital Universitari Vall d'Hebron Research Institute (`cardio:org-hospital-universitari-vall-d-hebron-research-institute`)

## Provenance

Content hash: 43ad773a1fc21c2c20b285289b729ea89836b8bcaf5857c4df14c85c926a8262
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
